BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switchi | IONS Message Board Posts

Ionis Pharmaceuticals, Inc.

  IONS website

IONS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  61331 of 61359  at  2/15/2020 4:23:42 PM  by

arthurs1


 In response to msg 61330 by  iyonwin
view thread

Re: BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switching from Spinraza at launch, compared to consensus, as historically physicians are less likely to switch out a working therapy.restricted label for Risdi

  I doubt we'll see any significant decline in Spinraza numbers in 2020. Nor 2021. Probably have growth in ex US sales..


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 186
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...